Details of the Drug Combinations

General Information of This Drug (ID: DMWZO21)

• Drug Name: FP-187 (DMWZO21)

Indication

Multiple sclerosis; ICD 11: 8A40; Status: Approved [1]; Secondary progressive multiple sclerosis; ICD 11: N.A.; Status: Approved [1]; Autoimmune diabetes; ICD 11: 5A10; Status: Phase 2 [2]

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
FP-187 + Ruxolitinib	DCQJP70	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BIIB-098 + FP-187	DCU31H5	BIIB-098	Multiple Sclerosis	[4]
Aspirin + FP-187	DCR07UL	Aspirin	Relapsing-Remitting Multiple Sclerosis	[5]
Montelukast + FP-187	DCJKXOF	Montelukast	Multiple Sclerosis	[6]

References

• [1] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [2] ClinicalTrials.gov (NCT01230138) Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
• [3] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [4] ClinicalTrials.gov (NCT05767736) A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
• [5] ClinicalTrials.gov (NCT02090413) Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
• [6] ClinicalTrials.gov (NCT02410278) Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera